Back to search results

OHB-607 for Preventing Bronchopulmonary Dysplasia in Premature Infants

This study is looking at whether an investigational drug called OHB-607 can help prevent Bronchopulmonary Dysplasia (BPD), a chronic lung disease, in extremely premature infants. Researchers want to see if OHB-607 can reduce the number of babies who develop severe BPD or die by 36 weeks after their expected birth date, compared to babies receiving standard care. Infants can join if they are 24 hours old or less. The study aims to enroll 338 infants. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 338 participants. It compares infants receiving OHB-607 to those receiving standard neonatal care.
What's involved
Participants will receive OHB-607 as an intravenous infusion from birth up to 29 weeks and 6 days after their expected birth date.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 36 weeks after the infant's expected birth date.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03253263

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Active, Not Recruiting
PHASE2Ages 0–24InterventionalPrevention
OHB Neonatology Ltd.
~295 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:OHB-607

At a glance

Recruiting sites
0 of 62 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Reduction in the incidence of severe Bronchopulmonary Dysplasia (BPD) at 36 weeks (±3 days) Postmenstrual Age (PMA), or death at or before 36 weeks PMA, whichever comes first as compared to the SNC group.
Measured over Baseline through 36 weeks postmenstrual age (PMA)

Conditions

Bronchopulmonary Dysplasia
Chronic Lung Disease of Prematurity
Intraventricular Hemorrhage
Retinopathy of Prematurity (ROP)

Explore related trials

Bronchopulmonary DysplasiaBronchopulmonary dysplasia of newbornIntraventricular Brain HemorrhageRetinopathy of Prematurity

NCT03253263

Where you'd take part

This study runs at 62 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Academisch Medisch Centrum Amsterdam

    Amsterdam-Zuidoost, North Holland, Netherlandsno site contact published

  • Arkansas Children's Hospital

    Little Rock, Arkansasno site contact published

  • Ashford and St. Peter's Hospitals NHS Trust - St. Peter's Hospital

    Chertsey, Surrey, United Kingdomno site contact published

  • Azienda Ospedaliera Di Padova

    Padova, Veneto, Italyno site contact published

  • Azienda Ospedaliero-Universitaria Careggi SOD Neonatologia e Terapia Intensiva Neonatale

    Florence, Italyno site contact published

  • Cedars Sinai Medical Center

    Los Angeles, Californiano site contact published

  • Centro Hospitalar Lisboa

    Lisbon, Portugalno site contact published

  • Centro Materno Infantil do Norte - Centro Hospital Universitario do Porto, E.P.E.

    Porto, Portugalno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Reduction in the incidence of severe Bronchopulmonary Dysplasia (BPD) at 36 weeks (±3 days) Postmenstrual Age (PMA), or death at or before 36 weeks PMA, whichever comes first as compared to the SNC group.Baseline through 36 weeks postmenstrual age (PMA)

    Severe BPD is defined by the modified NICHD severity grading